(PBUS) Invesco PureBeta MSCI USA - Ratings and Ratios

Exchange: BATS • Country: USA • Currency: USD • Type: Etf • ISIN: US46138E4614 • Large Blend

PBUS: Large-cap Stocks, Mid-cap Stocks, US Equities

Let me break this down for you. The Invesco PureBeta MSCI USA ETF (ticker: PBUS) is designed to track the performance of the large- and mid-capitalization segments of the U.S. equity market. It does this by investing at least 90% of its total assets in the securities that make up the underlying MSCI index. The index itself is compiled, maintained, and maintained by MSCI Inc., the index provider, following strict guidelines and mandated procedures. This fund is non-diversified, which means it can take larger positions in individual securities compared to a diversified fund.

Here’s what’s important: PBUS is listed on the BATS exchange and falls under the Large Blend ETF category. Its current assets under management (AUM) are approximately $6.17 billion USD. While the fund’s structure is straightforward, it’s worth noting that it’s built for investors and fund managers who value precision in tracking the index without unnecessary complexity. The fund’s design ensures low tracking error relative to its target index, making it a cost-effective tool for exposure to the U.S. large- and mid-cap equity market.

What’s often overlooked is the liquidity and trading volume of ETFs like PBUS. With a significant AUM and trading on a major exchange like BATS, this fund offers both individual investors and institutional managers the ability to enter and exit positions with minimal market impact. This liquidity, combined with its pure-beta strategy, makes it a reliable choice for those seeking efficient exposure to the U.S. equity market without the frills of active management.

One more thing: this fund is domiciled in the United States, which is important for tax considerations and regulatory considerations for international investors. The absence of certain financial metrics like P/E, P/E forward, P/B, and P/s in the provided data suggests that the fund’s performance is primarily evaluated based on its ability to replicate the index it tracks, rather than on traditional valuation metrics. This is common for index-tracking ETFs, as the focus is on replication accuracy and cost efficiency rather than stock selection or valuation ratios.

Additional Sources for PBUS ETF

PBUS ETF Overview

Market Cap in USD 5,892m
Category Large Blend
TER 0.04%
IPO / Inception 2017-09-22

PBUS ETF Ratings

Growth 5y 83.7%
Fundamental -
Dividend 54.1%
Rel. Strength 0.06
Analysts -
Fair Price Momentum 54.60 USD
Fair Price DCF -

PBUS Dividends

Dividend Yield 12m 0.96%
Yield on Cost 5y 2.19%
Annual Growth 5y 6.40%
Payout Consistency 96.2%

PBUS Growth Ratios

Growth Correlation 3m -50.8%
Growth Correlation 12m 86.5%
Growth Correlation 5y 81.7%
CAGR 5y 17.84%
CAGR/Max DD 5y 0.70
Sharpe Ratio 12m 1.65
Alpha 0.01
Beta 1.010
Volatility 20.07%
Current Volume 238.2k
Average Volume 20d 116.1k
What is the price of PBUS stocks?
As of March 31, 2025, the stock is trading at USD 55.71 with a total of 238,197 shares traded.
Over the past week, the price has changed by -3.38%, over one month by -4.78%, over three months by -5.48% and over the past year by +7.84%.
Is Invesco PureBeta MSCI USA a good stock to buy?
Yes. Based on ValueRay Analyses, Invesco PureBeta MSCI USA (BATS:PBUS) is currently (March 2025) a good stock to buy. It has a ValueRay Growth Rating of 83.68 and therefor a clear technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PBUS as of March 2025 is 54.60. This means that PBUS is currently overvalued and has a potential downside of -1.99%.
Is PBUS a buy, sell or hold?
Invesco PureBeta MSCI USA has no consensus analysts rating.
What are the forecast for PBUS stock price target?
According to ValueRays Forecast Model, PBUS Invesco PureBeta MSCI USA will be worth about 60.8 in March 2026. The stock is currently trading at 55.71. This means that the stock has a potential upside of +9.06%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 60.8 9.1%